New York State Teachers Retirement System Sells 24,507 Shares of Hims & Hers Health, Inc. $HIMS

New York State Teachers Retirement System decreased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 12.8% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 166,880 shares of the company’s stock after selling 24,507 shares during the period. New York State Teachers Retirement System owned about 0.07% of Hims & Hers Health worth $3,464,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. Norges Bank bought a new stake in shares of Hims & Hers Health in the fourth quarter worth about $62,153,000. Invesco Ltd. grew its stake in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Clear Street Group Inc. purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $87,372,000. Finally, Marex Group plc increased its holdings in Hims & Hers Health by 162.2% during the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after purchasing an additional 1,496,707 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the transaction, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. The trade was a 3.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells purchased 48,400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the purchase, the director owned 224,417 shares in the company, valued at $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders sold 167,161 shares of company stock valued at $5,041,152. 11.76% of the stock is currently owned by insiders.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $35.53 on Friday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock has a market cap of $8.22 billion, a P/E ratio of -394.80, a P/E/G ratio of 101.51 and a beta of 2.35. The business’s 50 day moving average price is $29.21 and its 200-day moving average price is $26.34. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the business earned $0.20 EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HIMS. Barclays increased their price objective on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, June 17th. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Citigroup raised their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $30.70.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.